These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

116 related items for PubMed ID: 1979968

  • 1. MIF-induced augmentation of melatonin functions: possible relevance to mechanisms of action of MIF-1 in movement disorders.
    Sandyk R.
    Int J Neurosci; 1990 May; 52(1-2):59-65. PubMed ID: 1979968
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Effects of L-prolyl-L-leucyl-glycine amide (MIF-I) on dopaminergic neurons.
    Kostrzewa RM, Spirtes MA, Klara JW, Christensen CW, Kastin AJ, Joh TH.
    Pharmacol Biochem Behav; 1976 May; 5(Suppl 1):125-7. PubMed ID: 13412
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. MIF-I and postsynaptic receptor sites for dopamine.
    Kostrzewa RM, Hardin JC, Snell RL, Kastin AJ, Coy DH, Bymaster F.
    Brain Res Bull; 1979 May; 4(5):657-62. PubMed ID: 39665
    [Abstract] [Full Text] [Related]

  • 8. Modification of d-amphetamine- or chlorpromazine-induced hypothermia by beta-endorphin, MIF-I, and alpha-MSH: mediation by the dopaminergic system.
    Yehuda S, Carasso RL.
    Peptides; 1982 May; 3(2):105-10. PubMed ID: 6124951
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Melanocyte-stimulating hormone and persistent tardive dyskinesia: a hypothesis.
    Sandyk R.
    Int J Neurosci; 1990 Mar; 51(1-2):45-52. PubMed ID: 1979965
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Partial protection from the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) by Pro-Leu-Gly-NH2(PLG; MIF-1).
    Sheng JG, Xu DL, Yu HZ, Xu XR, Tang QM.
    Life Sci; 1987 May 18; 40(20):2007-10. PubMed ID: 2437428
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The significance of eye blink rate in parkinsonism: a hypothesis.
    Sandyk R.
    Int J Neurosci; 1990 Mar 18; 51(1-2):99-103. PubMed ID: 2265915
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. MIF-1 attenuates spiroperidol alteration of striatal dopamine D2 receptor ontogeny.
    Saleh MI, Kostrzewa RM.
    Peptides; 1989 Mar 18; 10(1):35-9. PubMed ID: 2568624
    [Abstract] [Full Text] [Related]

  • 19. The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease.
    Chase TN.
    Drugs; 1998 Mar 18; 55 Suppl 1():1-9. PubMed ID: 9483164
    [Abstract] [Full Text] [Related]

  • 20. Failure of MIF-I to affect behavioral responses in patients with Parkinson's diseases under L-dopa therapy.
    Caraceni T, Parati EA, Girotti F, Celano I, Frigerio C, Cocchi D, Müller EE.
    Psychopharmacology (Berl); 1979 Jun 21; 63(3):217-22. PubMed ID: 39308
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.